Appendix 4E and 2026 Annual Report
Filed with ASX · · 77 pages · English
Summary by 6ix AI
The report indicates a loss from ordinary activities after tax, with no dividends declared during the financial period. The company reported an increase in net assets, attributed to capital raisings that offset operating losses.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- Appendix 4G and Corporate Governance Statement
- June 2026 Quarterly Update and Appendix 4C
- March 2026 Quarterly Update and Appendix 4C
- Appendix 4D and Half Year Financial Report
- December 2025 Quarterly Update and Appendix 4C
Later from Prescient Therapeutics
- Prescient Therapeutics Launches Share Purchase Plan for $7m
- Proposed issue of securities - PTX
- Share Purchase Plan Cleansing Notice
- Prescient Therapeutics Opens SPP to Raise $7m Today
- Prescient Share Purchase Plan Investor Presentation
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics